Data gathered: January 2
Alternative Data for NovaBay Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 4,259 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 19,699 | Sign up | Sign up | Sign up |
| Twitter Followers | 4,167 | Sign up | Sign up | Sign up |
| Twitter Mentions | 100 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 129 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 34 | Sign up | Sign up | Sign up |
| Linkedin Employees | 65 | Sign up | Sign up | Sign up |
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally.
| Price | $0.62 |
| Target Price | Sign up |
| Volume | 29,750 |
| Market Cap | $2.9M |
| Year Range | $0.38 - $6.1 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)December 27 - ETF Daily News |
 |
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's WhyDecember 25 - Yahoo |
 |
NovaBay Pharmaceuticals Adjourns Special Meeting Due to Insufficient VotesDecember 22 - ETF Daily News |
 |
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of StockholdersDecember 19 - Investing.com |
 |
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.comDecember 18 - ETF Daily News |
|
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.comDecember 13 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2.4M | 3.5M | 1.6M | -1.2M | -1.2M | -0.330 |
| Q2 '24 | 2.4M | 3.4M | 1.6M | -1.6M | -1M | -1.370 |
| Q1 '24 | 1.8M | 4.2M | 1.8M | -3.2M | -1.6M | -0.150 |
| Q4 '23 | 3.2M | 7.2M | 1.8M | -4.1M | -3.4M | -1.330 |
| Q3 '23 | 3.3M | 4.4M | 1.7M | -1.8M | -1.1M | -0.370 |
Insider Transactions View All
| Kunin Jeffrey filed to sell 1 shares at $2.1. December 5 '22 |
Similar companies
Read more about NovaBay Pharmaceuticals (NBY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of NovaBay Pharmaceuticals?
The Market Cap of NovaBay Pharmaceuticals is $2.9M.
What is the current stock price of NovaBay Pharmaceuticals?
Currently, the price of one share of NovaBay Pharmaceuticals stock is $0.62.
How can I analyze the NBY stock price chart for investment decisions?
The NBY stock price chart above provides a comprehensive visual representation of NovaBay Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NovaBay Pharmaceuticals shares. Our platform offers an up-to-date NBY stock price chart, along with technical data analysis and alternative data insights.
Does NBY offer dividends to its shareholders?
As of our latest update, NovaBay Pharmaceuticals (NBY) does not offer dividends to its shareholders. Investors interested in NovaBay Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of NovaBay Pharmaceuticals?
Some of the similar stocks of NovaBay Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.